New monthly shot could simplify mental health treatment

NCT ID NCT07185815

Recruiting now Disease control Sponsor: Mapi Pharma Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a long-acting injection of cariprazine given once a month, instead of daily pills, for people with schizophrenia, bipolar I disorder, or major depression. The trial involves 24 clinically stable adults and will check safety, side effects, and how well the drug works. It is still in early stages, so results are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cariprazine (long-acting injection)
What this could lead to: If successful, this could offer a convenient once-monthly injection for people with schizophrenia, bipolar disorder, or depression, potentially improving treatment adherence.
What could go wrong: This is an early-phase trial with only 24 participants, so safety and effectiveness are not yet proven. The injection may cause side effects or not work as well as daily pills.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR 1 DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar I disorder major depressive disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR 1 DISORDER BIPOLAR I DISORDER MAJOR DEPRESSIVE DISORDER MAJOR DEPRESSIVE DISORDER (MDD) SCHIZOPHRENIA

Contacts and locations

Locations

Mapi Pharma Investigational Site IL-001
RECRUITING

Tel Aviv, 6423906, Israel
Mapi Pharma Investigational Site IL-003
RECRUITING

Ness Ziona, 741000, Israel
Mapi Pharma Investigational Site IL-004
RECRUITING

Beersheba, 8461144, Israel
Mapi Pharma Investigational Site IL-005
RECRUITING

Ramat Gan, 56621, Israel
Mapi Pharma Investigational Site IN-101
RECRUITING

Ahmedabad, 380008, India
Mapi Pharma Investigational Site IN-102
RECRUITING

Ahmedabad, 380016, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.